English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

The diagnosis of a paraneoplastic syndrome (PNS) is challenging as it comprises a group of clinically heterogeneous entities, all related to a coexistent, but sometimes occult, malignancy.1 The detection of paraneoplastic antibodies aids the clinician to establish the diagnosis of a PNS.2 Paraneoplastic antibodies are screened for by means of immunohistochemistry or indirect immunofluorescence on cerebellar slices.2 Cerebellar substrates that can be used for screening for paraneoplastic antibodies are commercially available.3

Negative commercial screening test for paraneoplastic antibodies in a case of opsoclonus